Chemotherapy for advanced non-small cell lung cancer

Martin F. Dietrich, David E. Gerber

Research output: Chapter in Book/Report/Conference proceedingChapter

16 Scopus citations


Non-small cell lung cancer has seen an unprecedented augmentation of therapeutic options over the last couple of years. Improved understanding of molecular drivers and the role of the immune system in cancer therapy have brought new drugs to the armamentarium. Despite these advances, cytotoxic chemotherapy remains a substantial part of therapy for most patients in locally advanced and metastatic stage. Initially thought to be a chemotherapy-resistant entity, meta-analyses in the mid-1990s demonstrated modest efficacy of platinum-based therapy. Further combination trials demonstrated enhanced efficacy for several regimen in first and second lines, including the introduction of antimetabolites, taxanes, and anti-angiogenic agents. Maintenance chemotherapy has been another novel, successful approach for management of metastatic disease. Herein, we summarize the current concepts of chemotherapy, its applicability to the different histologies, and novel concepts of therapy.

Original languageEnglish (US)
Title of host publicationCancer Treatment and Research
PublisherKluwer Academic Publishers
Number of pages31
StatePublished - 2016

Publication series

NameCancer Treatment and Research
ISSN (Print)0927-3042


  • Advanced/metastatic disease
  • Chemotherapy
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Chemotherapy for advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this